Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.88)
# 1,712
Out of 4,915 analysts
47
Total ratings
37.84%
Success rate
58.78%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $10.71 | +40.12% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.49 | +663.05% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $10.97 | +173.47% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.07 | +1,956.07% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.59 | +329.34% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $17.51 | +613.88% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.45 | +634.69% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.02 | +529.14% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.18 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $6.20 | +9,577.42% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $183.03 | -56.74% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $46.80 | +231.20% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.31 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.01 | +315.97% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61,200 | $12.39 | +493,846.73% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $2.77 | +64,881.95% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $40.71 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.74 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.14 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $4.78 | +31,280.75% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $3.02 | +29,701.32% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.85 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $12.60 | +1,209.52% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $61.79 | +264.14% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.05 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.79 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $10.71
Upside: +40.12%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.49
Upside: +663.05%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $10.97
Upside: +173.47%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.07
Upside: +1,956.07%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.59
Upside: +329.34%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $17.51
Upside: +613.88%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.45
Upside: +634.69%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.02
Upside: +529.14%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.18
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $6.20
Upside: +9,577.42%
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $183.03
Upside: -56.74%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $46.80
Upside: +231.20%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $7.31
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $6.01
Upside: +315.97%
Apr 30, 2021
Initiates: Outperform
Price Target: $61,200
Current: $12.39
Upside: +493,846.73%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $2.77
Upside: +64,881.95%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $40.71
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.74
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.14
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $4.78
Upside: +31,280.75%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $3.02
Upside: +29,701.32%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.85
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $12.60
Upside: +1,209.52%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $61.79
Upside: +264.14%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.05
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.79
Upside: -